Effective strategies for the management of pyoderma gangrenosum

A comprehensive review

Forum Patel, Sarah Fitzmaurice, Christopher Duong, Young He, Jonathan Fergus, Siba P Raychaudhuri, Miki Shirakawa Garcia, Emanual Michael Maverakis

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilic infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, and adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalActa Dermato-Venereologica
Volume95
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Pyoderma Gangrenosum
Interleukin-17
LY2439821
Interleukin-23
Skin
Immunosuppressive Agents
Biological Products
Neutrophils
Therapeutics
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Adalimumab
  • Biologic
  • Infliximab
  • IVIG
  • Mycophenolate mofetil
  • Pyoderma gangrenosum

ASJC Scopus subject areas

  • Dermatology

Cite this

Effective strategies for the management of pyoderma gangrenosum : A comprehensive review. / Patel, Forum; Fitzmaurice, Sarah; Duong, Christopher; He, Young; Fergus, Jonathan; Raychaudhuri, Siba P; Shirakawa Garcia, Miki; Maverakis, Emanual Michael.

In: Acta Dermato-Venereologica, Vol. 95, No. 5, 2015, p. 525-531.

Research output: Contribution to journalArticle

Patel, Forum ; Fitzmaurice, Sarah ; Duong, Christopher ; He, Young ; Fergus, Jonathan ; Raychaudhuri, Siba P ; Shirakawa Garcia, Miki ; Maverakis, Emanual Michael. / Effective strategies for the management of pyoderma gangrenosum : A comprehensive review. In: Acta Dermato-Venereologica. 2015 ; Vol. 95, No. 5. pp. 525-531.
@article{04c1a3f8dbbe4a2a8c66aeba7060c4ba,
title = "Effective strategies for the management of pyoderma gangrenosum: A comprehensive review",
abstract = "Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilic infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, and adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.",
keywords = "Adalimumab, Biologic, Infliximab, IVIG, Mycophenolate mofetil, Pyoderma gangrenosum",
author = "Forum Patel and Sarah Fitzmaurice and Christopher Duong and Young He and Jonathan Fergus and Raychaudhuri, {Siba P} and {Shirakawa Garcia}, Miki and Maverakis, {Emanual Michael}",
year = "2015",
doi = "10.2340/00015555-2008",
language = "English (US)",
volume = "95",
pages = "525--531",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "5",

}

TY - JOUR

T1 - Effective strategies for the management of pyoderma gangrenosum

T2 - A comprehensive review

AU - Patel, Forum

AU - Fitzmaurice, Sarah

AU - Duong, Christopher

AU - He, Young

AU - Fergus, Jonathan

AU - Raychaudhuri, Siba P

AU - Shirakawa Garcia, Miki

AU - Maverakis, Emanual Michael

PY - 2015

Y1 - 2015

N2 - Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilic infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, and adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.

AB - Pyoderma gangrenosum (PG) is an inflammatory disease characterized by painful skin ulcerations with undermined and erythematous borders. The etiology of PG is not well understood, but it is generally considered to be an aberrant immune response characterized by a dermal neutrophilic infiltrate. Given the existence of only a few PG clinical trials, treatment options are largely based upon anecdotal data and small case studies. In addition to classic immunosuppressive medications, PG has been reported to respond well to the anti-TNF agents, infliximab, etanercept, and adalimumab. Newer biologics such as ustekinumab (anti-IL-23), ixekizumab (anti-IL-17) and brodalumab (anti-IL-17R) are promising given the effect of IL-17 on neutrophil migration. However, the effectiveness of these newer agents remains to be rigorously evaluated. Multi-drug regimens have not been well described in the literature but are an excellent alternative for patients with refractory disease. Herein, we provide a comprehensive review of the pathophysiology of PG and of the different treatments available for managing PG patients, including the theoretical benefit of initiating multidrug regimens. We also provide one possible treatment algorithm for patients with refractory disease and give examples of refractory PG cases successfully treated with multidrug regimens.

KW - Adalimumab

KW - Biologic

KW - Infliximab

KW - IVIG

KW - Mycophenolate mofetil

KW - Pyoderma gangrenosum

UR - http://www.scopus.com/inward/record.url?scp=84928166902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928166902&partnerID=8YFLogxK

U2 - 10.2340/00015555-2008

DO - 10.2340/00015555-2008

M3 - Article

VL - 95

SP - 525

EP - 531

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 5

ER -